| [1] |
WHO. Hepatitis B[EB/OL]. 2013 [201307] http: //www.who.int/mediacentre/factsheets/fs204/en/.
|
| [2] |
Malik AH,Lee WM.Chronic hepatitis B virus infection:treatment strategies for the next millennium[J].Ann Intern Med,2000,132(9):723-731.
|
| [3] |
Zoulim F,Poynard T,Degos F,et al.A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine[J].J Viral Hepat,2006,13(4):278-288.
|
| [4] |
Yang HJ,Lee JH,Kim YJ,et al.Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance[J].J Med Virol,2012,84(3):424-430.
|
| [5] |
Litwin S,Toll E,Jilbert AR,et al.The competing roles of virus replication and hepatocyte death rates in the emergence of drug-resistant mutants:theoretical considerations[J].J Clin Virol,2005,34(Suppl 1):S96-S107.
|
| [6] |
Davis BJ, Erlanson DA. Learning from our mistakes: the ′unknown knowns′ in fragment screening[J].Bioorg Med Chem Lett,2013,23(10):2 844-2 852.
|
| [7] |
Tang YH,Lin KJ,You QD.Application of 2D molecular fingerprints based on molecular similarity in visual screening[J].J China Pharm Univ(中国药科大学学报),2009,40(2):178-184.
|
| [8] |
Chen L,Li YY,Zhao Q,et al.ADME evaluation in drug discovery.10.Predictions of P-glycoprotein inhibitors using recursive partitioning and naive bayesian classification techniques[J].Mol Pharm,2011,8(3):889-900.
|
| [9] |
Myint KZ,Wang L,Tong Q,et al.Molecular fingerprint-based artificial neural networks QSAR for ligand biological activity predictions[J].Mol Pharm,2012,9(10):2 912-2 923.
|
| [10] |
Wikel JH,Dow ER.The use of neural networks for variable selection in QSAR[J].Bioorg Med Chem Lett,1993,3(4):645-651.
|
| [11] |
Leardi R,Boggia R,Terrile M.Genetic algorithms as a strategy for feature-selection[J].J Chemometrics,1992,6(5):267-281.
|
| [12] |
Friedman JH,Roosen CB.An introduction to multivariate adaptive regression splines[J].Stat Methods Med Res,1995,4(3):197-217.
|
| [13] |
Rogers D,Hopfinger AL.Application of genetic function approximation to quantitative structure-activity relationships and quantitative structure-property relationships[J].J Chem Inf Comput Sci,1994,34:854-866.
|
| [14] |
Fu X,Jiang S,Li C,et al.Design and synthesis of novel bis(L-amino acid)ester prodrugs of 9-[2-(phosphonomethoxy)ethyl]adenine(PMEA)with improved anti-HBV activity[J].Bioorg Med Chem Lett,2007,17(2):465-470.
|
| [15] |
Fu XZ,Ou Y,Pei JY,et al.Synthesis,anti-HBV activity and renal cell toxicity evaluation of mixed phosphonate prodrugs of adefovir[J].Eur J Med Chem,2012,49:211-218.
|
| [16] |
Choi JR,Cho DG,Roh KY,et al.A novel class of phosphonate nucleosides.9-[(1-phosphonomethoxycyclopropyl)methyl]guanine as a potent and selective anti-HBV agent[J].J Med Chem,2004,47:2 864-2 869.
|
| [17] |
Sekiya K,Takashima H,Udeda N,et al.2-Amino-6-arylthio-9-[2-(phosphonomethoxy)ethyl]purine bis(2,2,2-trifluoroethyl)esters as novel HBV-specific antiviral reagents[J].J Med Chem,2002,45(14):3 138-3 142.
|
| [18] |
Wang J,Singh US,Rawal RK,et al.Antiviral activity of novel 2′-fluoro-6′-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants[J].Bioorg Med Chem Lett,2011,21(21):6 328-6 331.
|
| [19] |
Zhang HW,Detorio M,Herman BD,et al.Synthesis,antiviral activity,cytotoxicity and cellular pharmacology of l-3′-azido-2′,3′-dideoxypurine nucleosides[J].Eur J Med Chem,2011,46(9):3 832-3 844.
|
下载:
